SCHEMBL471236

SCHEMBL471236

O=C/C=C/C1=CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
TRPA1 O75762 1/20 0.32
LMNA P02545 1/20 0.32
ALOX5 P09917 1/20 0.32
MAPK1 P28482 1/20 0.32
HDAC4 P56524 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
PIN1 Q13526 1/20 0.31
TRPV1 Q8NER1 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11094445 1.00 ALDH1A1 (0.32) ALDH1A1TRPA1LMNAALOX5MAPK1
SCHEMBL27541089 0.93
SCHEMBL9647720 0.81 KDM1A (0.34) HDAC4HDAC2HDAC8HDAC6PIN1
SCHEMBL9647725 0.81 KDM1A (0.34) HDAC4HDAC2HDAC8HDAC6PIN1
SCHEMBL2010366 0.79 KDM1A (0.33) HDAC4HDAC2HDAC8HDAC6PIN1
SCHEMBL8173640 0.78
SCHEMBL7500072 0.78
SCHEMBL18788052 0.77
SCHEMBL19817073 0.77
SCHEMBL197588 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368068-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES FIRMENICH SA (CH) 2024-11-07 US disclosed
EP-4367109-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES Firmenich SA (CH) 2024-05-15 EP disclosed
CN-117916227-A Process for preparing perfuming intermediates 弗门尼舍有限公司 2024-04-19 CN disclosed
WO-2023036732-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES FIRMENICH SA (CH) 2023-03-16 WO disclosed
EP-2196454-B1 EXO-AND DIASTEREO-SELECTIVE SYNTHESES OF HIMBACINE ANALOGS MERCK SHARP & DOHME (US) 2014-08-27 EP disclosed
EP-2399912-A2 An exo-selective synthesis of himbacine analogs Schering Corporation (US) 2011-12-28 EP disclosed
EP-2206697-A1 Exo- and diastereo-selective syntheses of himbacine analogs SCHERING CORPORATION (US) 2010-07-14 EP disclosed
EP-2196454-A2 Exo-and diastereo-selective syntheses of himbacine analogs SCHERING CORPORATION (US) 2010-06-16 EP disclosed
EP-1848705-B1 EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS SCHERING CORP (US) 2010-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368068-A1 PROCESS FOR PREPARING PERFUMING INTERMEDIATES POR, PPOX, ACLY ALDH1A1 709/4885TRPA1 256/4885LMNA 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.